Ranbaxy Launches Ran(R)-Tamsulosin Hydrochloride Capsules in Canada



    TORONTO, Nov. 20 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a
wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today
that RLL had received approval in Canada to manufacture and market Tamsulosin
Hydrochloride Capsules 0.4 mg from Health Canada, Therapeutic Products
Directorate (TPD).  This product has proven to be bio- equivalent to Flomax(R)
Capsules which is indicated for the treatment of Benign Prostatic Hyperplasia
(BPH).  The total market for both generic and brand Tamsulosin Hydrochloride
Capsules in Canada is CAD $22 million (IMS-MAT: March 2007).
    "We are pleased to receive this approval from TPD for Tamsulosin
Hydrochloride Capsules that will expand Ranbaxy's expanding product portfolio
of accessible and affordable generic product offerings.  We are also quite
proud of the fact that this formulation was fully developed within our parent
company Ranbaxy Laboratories Limited, which further demonstrates the
capabilities and competencies of the Ranbaxy organization.  This is the fourth
product to be added to our product portfolio through this pathway in 2007.
RPCI's Sales Team will be offering Ran(R)-Tamsulosin immediately under the
Ranbaxy label in all of the Canadian provinces that now provides another
option to pharmacist for this molecule, that will be of benefit to both
patients and the Canadian Health Care system," said Paul Drake, President,
RPCI.
    Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario,
Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),
India's largest pharmaceutical company.  RPCI is engaged in the sale and
distribution of generic prescription products in the Canadian healthcare
system.
    Ranbaxy Laboratories Limited, headquartered in India, is an integrated,
research based, international pharmaceutical company producing a wide range of
quality, affordable generic medicines, trusted by healthcare professionals and
patients across geographies.
    Ranbaxy's continued focus on R&D has resulted in several approvals in
developed markets and significant progress in New Drug Discovery Research. The
Company's foray into Novel Drug Delivery Systems has led to proprietary
"platform technologies", resulting in a number of products under development.
The Company is serving its customers in over 125 countries and has an
expanding international portfolio of affiliates, joint ventures and alliances,
ground operations in 49 countries and manufacturing operations in 11
countries.

    *Flomax(R) is a registered trademark of Boehringer Ingelheim, Canada

    
    CONTACTS:    Charles M. Caprariello
                 Vice President, Corporate Communications
                 Ranbaxy Inc.
                 (609) 720-5615
    

    
                 Paul Drake
                 President and General Manager
                 Ranbaxy Pharmaceuticals Canada, Inc
                 (905) 219-8820
    




For further information:

For further information: Charles M. Caprariello, Vice President,
Corporate  Communications of Ranbaxy Inc., +1-609-720-5615, or Paul Drake,
President and  General Manager of Ranbaxy Pharmaceuticals Canada, Inc,
+1-905-219-8820

Organization Profile

Ranbaxy Pharmaceuticals Canada Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890